除此之外,本次SABCS大会也更新了Ⅰ期临床研究SERENA-1研究中Camizestrant联合Capivasertib治疗ER+/HER2-晚期乳腺癌的疗效与安全性数据,入组的29例患者中,48%的患者既往接受过化疗,90%的患者既往接受过CDK4/6抑制剂治疗,55%的患者既往接受过氟维司群的治疗13。患者接受Camizestrant联合Capivasertib治疗的ORR达29.6...
[4]Oliveira M, Pominchuk D, Hamilton EP, et al. Clinical activity of camizestrant, a next-generation SERD, versus fulvestrant in patients with a detectable ESR1 mutation: Exploratory analysis of the SERENA-2 phase 2 ...
[4]Oliveira M, Pominchuk D, Hamilton EP, et al. Clinical activity of camizestrant, a next-generation SERD, versus fulvestrant in patients with a detectable ESR1 mutation: Exploratory analysis of the SERENA-2 phase 2 trial. 2023 ASCO. Abstract 1066. [5]Raheem F, Karikalan SA, Batalini ...
[1]Oliveira M, Pominchuk D, Hamilton EP, et al. Clinical activity of camizestrant, a next-generation SERD, versus fulvestrant in patients with a detectable ESR1 mutation: Exploratory analysis of the SERENA-2 phase 2 trial. 2023 ASCO. Abstract 1066. [2]Oliveira M, et al Camizestrant, a...
除上述SERENA-6研究外,Camizestrant在ER+早/晚期乳腺癌的其他III期临床研究也在进行中: SERENA-4研究:预计纳入1402例患者,旨在评估Camizestrant联合哌柏西利对比阿那曲唑联用哌柏西利一线治疗ER+局部晚期或转移性乳腺癌患者的疗效和安全性。 CAMBRIA-1研究:预计纳入4300例患者,比较Camizestrant和标准内分泌治疗的疗...
The results from the ongoing Phase 3 studies, SERENA-4 and SERENA-6, will further elucidate the role of this combination in the treatment of patients with HR+/HER2 ABC.Clinical trial information: NCT03616587.Mafalda OliveiraVall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain;Erika P...
Clinical activity of camizestrant, a next-generation SERD, versus fulvestrant in patients with a detectable ESR1 mutation: Exploratory analysis of the SERENA-2 phase 2 trial. 2023 ASCO. Abstract 1066. [2]Oliveira M, et al Camizestrant, a next generation oral SERD vs fulvestrant in post-...
除上述SERENA-6研究外,Camizestrant在ER+早/晚期乳腺癌的其他III期临床研究也在进行中: SERENA-4研究:预计纳入1402例患者,旨在评估Camizestrant联合哌柏西利对比阿那曲唑联用哌柏西利一线治疗ER+局部晚期或转移性乳腺癌患者的疗效和安全性。 CAMBRIA-1研究:预计纳入4300例患者,比较Camizestrant和标准内分泌治疗的疗...